Key facts
- This page summarizes Matthew B. Klein's Form 4 filing for PTC THERAPEUTICS, INC. (PTCT).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 28 Dec 2023, 17:12.
Matthew B. Klein - 28 Dec 2023 Form 4 Insider Report for PTC THERAPEUTICS, INC. (PTCT)
- Reporting relationship
- CHIEF EXECUTIVE OFFICER, Director
- Issuer ticker
- PTCT
- Reported as of
- 28 Dec 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 28 Dec 2023, 17:12:36 UTC
- Prior SEC filing
- 26 May 2023
- Next SEC filing
- 09 Jan 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Avraham S. Adler, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Matthew B. Klein filed Form 4 for PTC THERAPEUTICS, INC. (PTCT) on 28 Dec 2023.
Change
- Previous filing in this sequence was filed on 26 May 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
PTCT
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +75,000
- Change %
- +73%
- Price
- $0.000000
- Shares after
- 177,961
- Date
- 28 Dec 2023
- Ownership
- Direct
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Restricted stock unit granted on December 28, 2023 that vests in four equal installments over four years, commencing on December 29, 2023.
Footnote F2
Includes 316 shares of common stock acquired under the Issuer's employee stock purchase plan for the period ending June 30, 2023.